About BG Medicine (OTCMKTS:BGMD)
BG Medicine, Inc. engages in development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryLife Sciences Tools & Services
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$1.57 million
Price / Sales0.36
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
BG Medicine (OTCMKTS:BGMD) Frequently Asked Questions
What is BG Medicine's stock symbol?
BG Medicine trades on the OTCMKTS under the ticker symbol "BGMD."
How were BG Medicine's earnings last quarter?
BG Medicine (OTCMKTS:BGMD) released its quarterly earnings results on Tuesday, November, 17th. The medical research company reported ($0.27) earnings per share for the quarter. The medical research company earned $334 million during the quarter, compared to the consensus estimate of $695 million. View BG Medicine's Earnings History.
Who are some of BG Medicine's key competitors?
Some companies that are related to BG Medicine include Atlas Resource Partners (ARPJQ), Quiksilver (ZQKSQ), Inventergy Global (INVT), Goodrich Petroleum (GDPMQ), Digiliti Money Group (DGLT), DynaVox (DVOXQ), First NBC Bank (FNBC), Affymax (AFFY), Thunderbird Resources Equity (GMXRQ), TetraLogic (TLOG), AFREN (AFRNF), Education Management (EDMC), Seal123 (WTSLQ), Glori Energy (GLRI), Quantum Fuel Systems Technologies Worldwide (QTWWQ), Viewtran Group (VIEWF), Azure Midstream Pa Com Unit Ltd Partner Int (AZURQ) and Roust (CEDCQ).
Who are BG Medicine's key executives?
BG Medicine's management team includes the folowing people:
- Dr. Paul R. Sohmer M.D., Chief Exec. Officer, Pres and Director (Age 69)
- Mr. Stephen P. Hall, Chief Financial Officer, Exec. VP and Treasurer (Age 67)
- Dr. Aram Adourian Ph.D., Chief Scientific Officer and Sr. VP (Age 48)
- Dr. Noubar B. Afeyan Ph.D., Founder (Age 55)
Has BG Medicine been receiving favorable news coverage?
Media coverage about BGMD stock has trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. BG Medicine earned a news impact score of 0.05 on Accern's scale. They also assigned media stories about the medical research company an impact score of 45.79 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of BG Medicine?
Shares of BGMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BG Medicine's stock price today?
One share of BGMD stock can currently be purchased for approximately $0.05.
How big of a company is BG Medicine?
BG Medicine has a market capitalization of $450,000.00 and generates $1.57 million in revenue each year.
How can I contact BG Medicine?
BG Medicine's mailing address is 303 Wyman Street Suite 300, Waltham MA, 02451. The medical research company can be reached via phone at 781-890-1199 or via email at [email protected]
MarketBeat Community Rating for BG Medicine (BGMD)MarketBeat's community ratings are surveys of what our community members think about BG Medicine and other stocks. Vote "Outperform" if you believe BGMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BGMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
BG Medicine (OTCMKTS:BGMD) Analyst Ratings History
(Data available from 4/20/2016 forward)
BG Medicine (OTCMKTS:BGMD) Earnings History and Estimates Chart
BG Medicine (OTCMKTS BGMD) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/4/2016||Q4 2015||($0.08)||$0.29 million||View||N/A|
|11/17/2015||Q315||($0.27)||$695.00 million||$334.00 million||View||N/A|
|5/14/2015||Q115||($0.03)||($0.04)||$1.60 million||$0.44 million||View||Listen|
|11/13/2014||Q3 2014||($0.28)||$0.70 million||View||N/A|
|8/14/2014||Q214||($0.06)||($0.06)||$1.40 million||$2.20 million||View||N/A|
|5/14/2014||Q114||($0.08)||($0.08)||$1.30 million||$0.7390 million||View||N/A|
|3/20/2014||Q413||($0.12)||($0.06)||$1.10 million||$1.15 million||View||N/A|
|11/6/2013||Q3 2013||($0.68)||($0.52)||$1.02 million||$1.03 million||View||N/A|
|8/8/2013||Q2 2013||($0.20)||($0.18)||$1.27 million||$1.00 million||View||N/A|
|5/9/2013||Q1 2013||($0.27)||($0.21)||$1.16 million||$0.8880 million||View||N/A|
BG Medicine (OTCMKTS:BGMD) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
BG Medicine (OTCMKTS BGMD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.50%
BG Medicine (OTCMKTS BGMD) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/9/2015||Noubar Afeyan||Director||Sell||46,438||$0.56||$26,005.28|| |
|12/11/2014||Edwin M Kania Jr||Major Shareholder||Sell||634,390||$0.32||$203,004.80|| |
|1/30/2013||Stelios Papadopoulos||Director||Buy||250,000||$2.00||$500,000.00|| |
|11/19/2012||Brian S Posner||Director||Buy||10,000||$1.17||$11,700.00|| |
|11/15/2012||Stephane Bancel||Chairman||Buy||100,000||$1.26||$126,000.00|| |
BG Medicine (OTCMKTS BGMD) News Headlines
BG Medicine (OTCMKTS:BGMD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
BG Medicine (OTCMKTS:BGMD) Income Statement, Balance Sheet and Cash Flow Statement
BG Medicine (OTCMKTS BGMD) Stock Chart for Friday, April, 20, 2018